Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.83 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | MAOB | P27338 | 1/20 | 0.83 |
| ▸ | PDE4A | P27815 | 1/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7289476 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7289463 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7305368 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7544542 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7544538 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7305359 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL5967914 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL633262 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL633263 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL29471410 | 0.91 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2A 1801/4885ADORA3 3648/4885ADORA2B 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.